Status:
ENROLLING_BY_INVITATION
Theta-burst Stimulation on Cognitive Function in the Patients with Young-onset Alzheimer's Disease Dementia
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Alzheimer Disease, Early Onset
Eligibility:
All Genders
50-75 years
Phase:
NA
Brief Summary
Young-onset dementia (YOD) is a devastating condition, and it produces substantial psychosocial impacts on individual's functioning and family's care burden. Alzheimer's disease (AD) dementia is the m...
Detailed Description
The investigators apply the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria to recruit the biomarker-defined, young-onset AD patients with intermediate-to-high levels of biologic...
Eligibility Criteria
Inclusion
- Any patient has a definite diagnosis of AD dementia according to the NIA-AA criteria for intermediate-to-high levels of biological evidence of probable and possible AD dementia (McKhann et al. 2011).
- Dementia onset before age 65 years old.
- Age between 50-75 years old for patient and control group.
- The severity of dementia is limited to mild to moderate stage in current project. The definition of mild to moderate stage of dementia is based on the clinical dementia rating scale (CDR) from 0.5-2.
- Cognitively normal controls MMSE≧24, CDR should be 0.
- Informed consent provided by the patient and family.
Exclusion
- Any subject has a definite diagnosis of epilepsy or history of seizure attack.
- Current or past history of clinically significant neurological insults affecting brain structure or function like completed stroke, head injury or brain tumor.
- Any subject has clinically significant or unstable medical diseases including metabolic, renal, liver, lung or cardiovascular disorders including metabolic, renal, liver, lung or cardiovascular disorders
- Any subject has current alcohol or other substances abuse and/ or dependence within the recent one year, or previously prolonged history of substances abuse
- Any females who is pregnant or lactating
- General MRI, TMS and/or PET exclusion criteria including subjects who had received brain aneurysm surgery, or implanted pacemaker, mechanical valves, cochlear implant or other metal devices/ objects that are not magnetic resonance (MR) compatible in the body.
- Any subject has allergic reaction to 18F-florbetapir or 18F-FDG radiotracers.
Key Trial Info
Start Date :
January 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04042532
Start Date
January 3 2020
End Date
June 30 2026
Last Update
February 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Taoyuan District, Guishan, Taiwan, 333